Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 98.50 +1.50 (+1.55%)
As of 07/3/2026 08:27 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, ODX, and CNSL

Should you buy INSPECS Group stock or one of its competitors? MarketBeat compares INSPECS Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Omega Diagnostics Group (ODX), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.86£6.54M£16.2424.55
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

21.6% of Tristel shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -2.67%-6.07%0.45%

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

Tristel currently has a consensus price target of GBX 400, suggesting a potential upside of 0.34%. INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 39.09%. Given Tristel's higher probable upside, research analysts clearly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has a beta of 0.339, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market.

Summary

Tristel beats INSPECS Group on 11 of the 15 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

BATM Advanced Communications has a beta of 0.754, indicating that its stock price is 25% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, indicating that its stock price is 61% more volatile than the broader market.

INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 39.09%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-14.90% -22.13% 0.58%
INSPECS Group -2.67%-6.07%0.45%

In the previous week, BATM Advanced Communications' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
BATM Advanced Communications Neutral
INSPECS Group Neutral

16.6% of BATM Advanced Communications shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 31.0% of BATM Advanced Communications shares are owned by insiders. Comparatively, 21.0% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BATM Advanced Communications has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£123.20M0.40-£278.26K-£4.20N/A
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

Summary

INSPECS Group beats BATM Advanced Communications on 8 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

0.4% of INSPECS Group shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Akers Biosciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences£2.32M0.00N/A-£129.60N/A
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 39.09%. Given Akers Biosciences' higher possible upside, research analysts plainly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
INSPECS Group Neutral

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -2.67%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A N/A N/A
INSPECS Group -2.67%-6.07%0.45%

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

Omega Diagnostics Group (LON:ODX) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 39.09%. Given Omega Diagnostics Group's higher possible upside, equities analysts clearly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Omega Diagnostics Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

Omega Diagnostics Group has a beta of 3.85, indicating that its share price is 285% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, indicating that its share price is 61% more volatile than the broader market.

29.8% of Omega Diagnostics Group shares are held by institutional investors. Comparatively, 0.4% of INSPECS Group shares are held by institutional investors. 50.6% of Omega Diagnostics Group shares are held by company insiders. Comparatively, 21.0% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Omega Diagnostics Group's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Omega Diagnostics Group Neutral
INSPECS Group Neutral

INSPECS Group has a net margin of -2.67% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -6.07% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Omega Diagnostics Group-51.15% -29.14% -10.53%
INSPECS Group -2.67%-6.07%0.45%

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

INSPECS Group (LON:SPEC) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -2.67%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Cambridge Nutritional Sciences has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.80

INSPECS Group has a beta of 1.607, indicating that its share price is 61% more volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

0.4% of INSPECS Group shares are owned by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

INSPECS Group presently has a consensus target price of GBX 60, indicating a potential downside of 39.09%. Given INSPECS Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Cambridge Nutritional Sciences Neutral

Summary

INSPECS Group and Cambridge Nutritional Sciences tied by winning 7 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£105.90M£3.08B£7.17B£2.74B
Dividend Yield2.00%1.91%2.66%6.15%
P/E Ratio-10.4817.0427.75368.96
Price / Sales0.52109.37535.1785,974.72
Price / Cash1.63146.5429.6527.87
Price / Book0.982.5510.977.75
Net Income-£4.11M£99.80M£3.57B£5.89B
7 Day Performance-1.50%0.91%2.12%0.55%
1 Month Performance16.57%1.55%5.25%-0.34%
1 Year Performance98.99%-6.41%33.29%70.53%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 98.50
+1.5%		GBX 60
-39.1%		+104.9%£105.90M£191.70MN/A1,673
TSTL
Tristel
0.6852 of 5 stars		GBX 401.25
+1.8%		GBX 400
-0.3%		-4.2%£192.54M£49.54M24.71208
BVC
BATM Advanced Communications
N/AGBX 14.60
-0.7%		N/A-5.8%£49.65M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel